Novartis: launches treatment for substance use disorder
(CercleFinance.com) - Novartis' unit Sandoz and US partner Pear Therapeutics announced on Tuesday the commercial launch of reSET, a 90-day prescription digital therapeutic for patients with substance use disorder, a chronic disease caused by the recurrent use of alcohol or drugs.
Used in conjunction with outpatient treatment under the supervision of a clinician, reSET provides cognitive behavioural therapy for patients of 18 years and older.
This first and only FDA-authorized prescription digital therapeutic is available immediately.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Used in conjunction with outpatient treatment under the supervision of a clinician, reSET provides cognitive behavioural therapy for patients of 18 years and older.
This first and only FDA-authorized prescription digital therapeutic is available immediately.
Copyright (c) 2018 CercleFinance.com. All rights reserved.